145591-80-6

Usage

Uses

Used in Pharmaceutical Research:
Cyclopropanecarboxylic acid, 1-[(phenylamino)carbonyl]-, is used as a building block in pharmaceutical research for the synthesis of various compounds. Its versatility and reactivity contribute to the development of new drugs and biologically active molecules, enhancing the discovery of potential therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Cyclopropanecarboxylic acid, 1-[(phenylamino)carbonyl]-, serves as a key component in the design and synthesis of complex molecular structures. Its unique properties allow for the creation of innovative compounds with potential therapeutic applications.
Used in Organic Synthesis:
Cyclopropanecarboxylic acid, 1-[(phenylamino)carbonyl]-, is employed as a valuable building block in organic synthesis, enabling the formation of a wide range of chemical compounds. Its reactivity and structural features make it an essential tool in the synthesis of specialty chemicals and other organic compounds.
Used in Chemical Processes:
Cyclopropanecarboxylic acid, 1-[(phenylamino)carbonyl]also finds application as a reagent in various chemical processes, where its unique properties contribute to the efficiency and effectiveness of the reactions involved. Its use in these processes further highlights its versatility and importance in the field of chemistry.

Upstream product

• 3697-66-3 1,1-cyclopropanedicarboxylic acid monoethyl ester 
• 541-41-3 chloroformic acid ethyl ester 
• 34782-60-0 cyclopropane-1,1-dicarboxylic acid dichloride 
• 62-53-3 aniline 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 1345847-73-5 methyl 1-(phenylcarbamoyl)cyclopropanecarboxylate 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 113117-83-2 ethyl (phenylcarbamoyl)cyclopropanecarboxylate 
• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 
• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 

Downstream Products

• 928038-25-9 [4-(3-fluoro-4-{[1-(phenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester 
• 1221443-11-3 N'-(4-(7-(4-oxaspiro[2.4]heptane-6-yloxy)quinolin-4-yloxy)-3-fluorophenyl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 1221443-04-4 N'-(4-(7-(3-(1-hydroxycyclopropyl)propoxy)quinolin-4-yloxy)-3-fluorophenyl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 1221443-03-3 N'-(4-(7-(((5R)-4-oxaspiro[2.4]heptane-5-yl)methoxy)quinolin-4-yloxy)-3-fluorophenyl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 1221442-99-4 N'-(4-(7-(3-(7-hydroxy-5-azaspiro[2.4]heptane-5-yl)propoxy)quinolin-4-yloxy)-3-fluorophenyl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 849221-94-9 N-{4-[6,7-dimethoxyquinolin-4-yl-oxy]phenyl}-N'-phenylcyclopropanedicarboxamide 
• 1195778-83-6 N-[4-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-a]pyridin-6-yl}oxy)-3-fluorophenyl]-N'-phenylcyclopropane-1,1-dicarboxamide hydrochloride 
• 1195778-92-7 N-[4-({2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}oxy)-3-fluorophenyl]-N'-phenylcyclopropane-1,1-dicarboxamide 
• 1221443-50-0 N'-(3-fluoro-4-(7-hydroxyquinolin-4-yloxy)phenyl)-N-phenylcyclopropane-1,1-dicarboxamide 
• 1609678-59-2 cyclopropane-1,1-dicarboxylic acid (3-ethynyl-phenyl)-amide phenylamide 
• 1345847-87-1 N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N'-phenylcyclopropane-1,1-dicarboxamide 
• 1345847-85-9 N-(4-(2-chloropyridin-4-yloxy)-2,5-difluorophenyl)-N'-phenylcyclopropane-1,1-dicarboxamide 

Relevant academic research and scientific papers

Preparation method of cabozantinib defluorination impurity

The invention discloses a preparation method of a cabozantinib defluorination impurity. The method comprises the following steps: preparing an intermediate 1, preparing 4-chloro-6, 7-dimethoxyquinoline, preparing an intermediate 2, and removing fluorine i

Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2

Both c-Met and VEGFR-2 were important targets for cancer therapies. In order to develop reversible and non-covalent c-Met and VEGFR-2 dual inhibitors, a series of [1,4]dioxino[2,3-f]quinazoline derivatives were designed and synthesized. The enzyme assay demonstrated that most target compounds had inhibition potency on both c-Met and VEGFR-2 with IC50 values in nanomolar range especially compounds 7m and 7k. Based on further cell proliferation assay in vitro, compound 7k showed significantly anti-tumor activity in vivo on a hepatocellular carcinoma (MHCC97H cells) xenograft mouse model. We docked the compound 7m with c-Met and VEGFR-2 kinases, and interpreted the SAR of these analogues. All results indicated that the target compounds were dual inhibitors of c-Met and VEGFR-2 kinases that held promising potential in cancer therapy.

A novel indazoles derivatives and use thereof

The invention belongs to the field of medical technology, relates to a structure of the formula (I) as shown in the model of the indazoles compound, its pharmaceutically acceptable acid to form the salt, wherein R1 And Ar such as rights are defined in the specification. Some compounds of pharmacological activity screening result display its MKN45 human gastric cancer cells, human lung adenocarcinoma cell A549, HT29 human colon cancer cells and human leukemia cell line K562 with obvious inhibition action, has good anti-tumor drug development application prospect.

Preparation method of impurities in synthesis of cabozantinib malate

Belonging to the field of chemical pharmacy, the invention discloses a preparation method of impurities in synthesis of cabozantinib malate. The impurities include KB-2-A, KB-A and SM-3-B. The invention also provides a preparation method of impurity KB-2-

Preparation and applications for novel 1,1-cyclopropyl diamide derivative

The invention discloses preparation and applications for a novel 1,1-cyclopropyl diamide derivative, and relates to a novel 1,1-cyclopropyl diamide derivative having a formula (I) and a salt thereof,including a medicinal salt, wherein R1, R2, R3, R4 and R

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

A series of novel hybrid structure derivatives, containing both LEE011 and Cabozantinib pharmacophore, were designed, synthesized and evaluated. Surprisingly, a compound 4d was discovered that highly exhibited effective and selective activity of CDK9 inhi

Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1) has attracted extensive attention as a novel antidiabetic target in the last decade. Several FFA1 agonists reported in the literature have been suffered from relatively high molecular weight and lipophilicity. We have previously reported the FFA1 agonist 1. Based on the common amide structural characteristic of SAR1 and NIH screened compound, we here describe the continued structure-activity exploration to decrease the molecular weight and lipophilicity of the compound 1 series by converting various amide linkers. All of these efforts lead to the discovery of the preferable lead compound 18, a compound with considerable agonistic activity, high LE and LLE values, lower lipophilicity than previously reported agonists, and appreciable efficacy on glucose tolerance in both normal and type 2 diabetic mice.

SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to substituted pyrimidinyl- and pyridinylpyrrolopyridinone compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.

Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and cellular activity

Both c-Met and VEGFR-2 are important targets for cancer therapies. Here we report a series of potent dual c-Met and VEGFR-2 inhibitors bearing an anilinopyrimidine scaffold. Two novel synthetic protocols were employed for rapid analoguing of the designed

CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES

The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: Formula I or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.